FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2575-2577 June 19, 2003 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Heeschen, C. PubMed Citation

To the Editor: Heeschen et al. (March 20 issue)¹ show that troponin T and soluble CD40 ligand independently predict the outcome in patients with acute coronary syndromes and that the increased risk conferred by elevated CD40 ligand levels is reduced by abciximab. They show that elevated levels of soluble CD40 ligand predict adverse outcome even in patients who are negative for troponin T, but they do not indicate whether patients who are troponin T–positive and have low levels of soluble CD40 ligand have an increased risk of adverse events, or whether this group also benefits from treatment with abciximab. This . . . [Full Text of this Article]

This article has been cited by other articles:

• Ueland, T., Jemtland, R., Godang, K., Kjekshus, J., Hognestad, A., Omland, T., Squire, I. B., Gullestad, L., Bollerslev, J., Dickstein, K., Aukrust, P. (2004). Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 44: 1970-1976 [Abstract] [Full Text]